Analysts at Guggenheim initiated coverage on shares of Celgene Corporation (NASDAQ:CELG) in a report released on Monday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. Zacks Investment Research raised Celgene Corporation from a “hold” rating to a “buy” rating and set a $151.00 target price for the company in a report on Tuesday, July 18th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $150.00 target price on shares of Celgene Corporation in a report on Friday, July 14th. Vetr lowered Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $149.76 target price for the company. in a report on Friday, July 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $160.00 target price on shares of Celgene Corporation in a report on Tuesday, July 11th. Finally, Bank of America Corporation reaffirmed a “buy” rating and set a $153.00 target price on shares of Celgene Corporation in a report on Monday, July 10th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. Celgene Corporation presently has an average rating of “Buy” and an average target price of $149.52.

Shares of Celgene Corporation (NASDAQ CELG) traded up 0.86% during midday trading on Monday, reaching $122.37. 7,666,547 shares of the company’s stock were exchanged. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $147.17. The firm has a 50 day moving average price of $140.79 and a 200 day moving average price of $130.41. The company has a market cap of $95.74 billion, a P/E ratio of 37.90 and a beta of 1.88.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.44 EPS. Equities research analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/23/celgene-corporation-celg-coverage-initiated-by-analysts-at-guggenheim.html.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,233 shares of company stock valued at $6,268,259. 0.95% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Arcadia Investment Management Corp MI raised its holdings in Celgene Corporation by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares in the last quarter. Thompson Davis & CO. Inc. raised its holdings in Celgene Corporation by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in Celgene Corporation in the first quarter worth $118,000. Motco raised its holdings in Celgene Corporation by 19.3% in the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares in the last quarter. Finally, Balentine LLC raised its holdings in Celgene Corporation by 83.5% in the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 481 shares in the last quarter. Institutional investors and hedge funds own 79.24% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

The Fly

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.